Frank H. Laukien - 11 May 2022 Form 4/A - Amendment Insider Report for BRUKER CORP (BRKR)

Role
PRESIDENT & CEO, Director, 10%+ Owner
Signature
/s/ Sara Hussain, Attorney-in-Fact
Issuer symbol
BRKR
Transactions as of
11 May 2022
Transactions value $
$98,559
Form type
4/A - Amendment
Filing time
17 May 2022, 16:02:30
Date Of Original Report
16 May 2022
Previous filing
22 Feb 2022
Next filing
09 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRKR Common Stock Purchase $98.6K +1.71K +0% $57.64 38.5M 11 May 2022 Direct F1
holding BRKR Common Stock 1.05M 11 May 2022 By Former Spouse F2
holding BRKR Common Stock 337K 11 May 2022 By Son F2
holding BRKR Common Stock 337K 11 May 2022 By Daughter F2
holding BRKR Common Stock 202K 11 May 2022 As UTMA Custodian for Son
holding BRKR Common Stock 71.7K 11 May 2022 As UTMA Custodian for Son
holding BRKR Common Stock 492 11 May 2022 By Former Spouse F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.30 to $57.98, inclusive. The reporting person undertakes to provide to Bruker Corporation, any security holder of Bruker Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reporting person disclaims beneficial ownership of 1,046,499 shares held by the reporting person's former spouse- Robyn Laukien, 492 shares held by the reporting person's former spouse- Ruta Laukien, 337,087 shares held by the reporting person's adult son and 336,607 shares held by the reporting person's adult daughter, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Remarks:

The purchases reported on the original Form 4 filed on May 16, 2022 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), with sales of shares by the reporting person on February 18, 2022. The reporting person has made arrangements with Bruker Corporation to voluntarily disgorge the full amount of statutory 'profit' calculated pursuant to Section 16(b) of the Exchange Act.